- Market Capitalization, $K 4,005,063
- Shares Outstanding, K 31,047
- Annual Sales, $ 311,330 K
- Annual Income, $ -9,020 K
- 60-Month Beta 1.94
- Price/Sales 12.93
- Price/Cash Flow N/A
- Price/Book 5.63
|Period||Period Low||Period High||Performance|
| || |
-3.76 (-2.85%)since 06/09/20
| || |
+31.78 (+32.99%)since 04/09/20
| || |
-49.71 (-27.96%)since 07/09/19
Analyst affirms Buy rating in G.W. Pharmaceuticals (GWPH) stock. Since hitting its low in March, G.W. Pharmaceuticals ( GWPH ) stock has climbed to about $130 per share. The company, which...
This week in the cannabis sector, we saw news out of Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), and GW Pharmaceuticals (GWPH) This week was another disappointing week for...
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba
The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?
GW's cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD)
The Latest report about the market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the...
This week in the Marijuana Weekly Recap, we report on news released from Aurora Cannabis (ACB) and HEXO (HEXO), and update readers on GW Pharmaceuticals (GWPH) After a devastating plunge in the...